Mesenchymal stem cells derived from umbilical cord tissue could help treat ARDS in Covid-19 patients, according to results of a Phase I/IIa clinical trial published by University of Miami researchers.

Novartis inked an exclusive worldwide license and collaboration deal with Australia-based Mesoblast to develop, commercialize and manufacture remestemcel-L for acute respiratory distress syndrome (ARDS), including when it is linked to Covid-19.

Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.